Press releaseBusiness Wire
Novocure
NVCR · NASDAQ
$14.68−$0.42 (−2.78%)TodayMarket closed ·
Prev close $15.10
Latest news
- Press releaseBusiness Wire
Novocure to Report Third Quarter 2026 Financial Results
- Press releaseBusiness Wire
Novocure Announces Upcoming Investor Events
- NewsAkanksha Bakshi
NovoCure's Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding
- NewsAvi Kapoor
Crude Oil Rises Sharply; T-Mobile Shares Fall Following Q2 Results
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsAvi Kapoor
Lockheed Martin, Quest Diagnostics, Thermo Fisher Scientific And Other Big Stocks Moving Higher On Thursday
- News
Transcript: NovoCure Q2 2026 Earnings Conference Call
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
Earnings Scheduled For July 23, 2026
- Press releaseBusiness Wire
Novocure Reports Second Quarter 2026 Financial Results
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
- Press releaseBusiness Wire
Novocure to Report Second Quarter 2026 Financial Results
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
- Press releaseBusiness Wire
Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
- Press releaseBusiness Wire
NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm
- Press releasePRNewswire
Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)
- NewsAvi Kapoor
Crude Oil Down 2%; Accenture Shares Fall After Q3 Results
- NewsVandana Singh
Novocure Brain Cancer Study Shows No Significant Survival Benefit, Stock Tanks
- Press releaseBusiness Wire
Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
NovoCure Reports Q1 2026 Results: Full Earnings Call Transcript
- Press releaseBusiness Wire
Novocure Reports First Quarter 2026 Financial Results
- Press releaseBusiness Wire
Novocure to Report First Quarter 2026 Financial Results
- NewsVandana Singh
NovoCure Tumor Treating Fields Shows Improved Outcomes In Tough Pancreatic Cancer
- Press releaseBusiness Wire
Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer
- Press releaseBusiness Wire
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
- Press releaseBusiness Wire
Novocure to Participate in 2026 Leerink Global Healthcare Conference
- News
NovoCure Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
- Press releaseBusiness Wire
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
- NewsAvi Kapoor
S&P 500 Falls Over 1%; American Electric Power Shares Gain After Upbeat Earnings
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.